Q3 Earnings Estimate for Prothena Issued By Zacks Research

Prothena Co. plc (NASDAQ:PRTA) – Equities researchers at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Prothena in a report released on Monday, April 21st. Zacks Research analyst E. Bagri now expects that the biotechnology company will earn ($1.29) per share for the quarter, down from their previous forecast of ($1.28). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($4.13) EPS, Q1 2027 earnings at ($1.30) EPS and FY2027 earnings at ($3.78) EPS.

Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $48.00 price target on shares of Prothena in a report on Friday, February 21st. Royal Bank of Canada reduced their target price on shares of Prothena from $24.00 to $20.00 and set a “sector perform” rating on the stock in a research note on Friday, February 21st. Oppenheimer increased their price target on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a research note on Friday, February 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Finally, StockNews.com upgraded Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prothena presently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Prothena Price Performance

Shares of Prothena stock opened at $9.70 on Thursday. The stock’s 50 day simple moving average is $12.45 and its 200-day simple moving average is $14.19. The stock has a market cap of $522.12 million, a P/E ratio of -4.22 and a beta of 0.07. Prothena has a 1-year low of $9.00 and a 1-year high of $25.42.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). The firm had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.

Institutional Investors Weigh In On Prothena

A number of institutional investors have recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. purchased a new position in Prothena during the 1st quarter valued at about $126,000. Duncan Williams Asset Management LLC lifted its position in shares of Prothena by 27.7% during the first quarter. Duncan Williams Asset Management LLC now owns 88,339 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 19,140 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Prothena by 92.9% in the first quarter. SG Americas Securities LLC now owns 72,559 shares of the biotechnology company’s stock valued at $898,000 after purchasing an additional 34,947 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Prothena by 48.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 77,637 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 25,353 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company’s stock worth $74,000 after buying an additional 5,875 shares during the period. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.